Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

January 22, 2008

Primary Completion Date

January 18, 2012

Study Completion Date

May 16, 2018

Conditions
Gastrointestinal Stromal Tumor
Interventions
DRUG

dasatinib

Dasatinib is given orally 70 mg BID. Dasatinib will be continued until progression, unacceptable toxicity and up to 2 years (26 cycles, each cycle lasting 4 weeks).

Trial Locations (18)

8002

Onkozentrum - Klinik im Park, Zurich

33076

Institut Bergonie, Bordeaux

67065

Centre Paul Strauss, Strasbourg

69437

Hopital Edouard Herriot - Lyon, Lyon

FI-00290

Biomedicum Helsinki, Helsinki

F-94805

Institut Gustave Roussy, Villejuif

D-45122

Universitaetsklinikum Essen, Essen

CH-5404

Kantonsspital Baden, Baden

CH-4016

Saint Claraspital AG, Basel

CH-4031

Universitaetsspital-Basel, Basel

CH-4101

Kantonsspital Bruderholz, Bruderholz

CH-7000

Kantonsspital Graubuenden, Chur

CH-1211

Hopital Cantonal Universitaire de Geneve, Geneva

CH-1011

Centre Hospitalier Universitaire Vaudois, Lausanne

CH-4410

Kantonsspital Liestal, Liestal

CH-9007

Kantonsspital - St. Gallen, Sankt Gallen

CH-8063

City Hospital Triemli, Zurich

CH-8091

UniversitaetsSpital Zuerich, Zurich

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT00568750 - Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors | Biotech Hunter | Biotech Hunter